JP2021500028A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500028A5
JP2021500028A5 JP2020522004A JP2020522004A JP2021500028A5 JP 2021500028 A5 JP2021500028 A5 JP 2021500028A5 JP 2020522004 A JP2020522004 A JP 2020522004A JP 2020522004 A JP2020522004 A JP 2020522004A JP 2021500028 A5 JP2021500028 A5 JP 2021500028A5
Authority
JP
Japan
Prior art keywords
seq
sequence represented
represented
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020522004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500028A (ja
JP7383607B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/056789 external-priority patent/WO2019079772A1/en
Publication of JP2021500028A publication Critical patent/JP2021500028A/ja
Publication of JP2021500028A5 publication Critical patent/JP2021500028A5/ja
Priority to JP2023190846A priority Critical patent/JP7650336B2/ja
Application granted granted Critical
Publication of JP7383607B2 publication Critical patent/JP7383607B2/ja
Priority to JP2025038002A priority patent/JP2025090718A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020522004A 2017-10-20 2018-10-19 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法 Active JP7383607B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023190846A JP7650336B2 (ja) 2017-10-20 2023-11-08 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法
JP2025038002A JP2025090718A (ja) 2017-10-20 2025-03-11 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762575275P 2017-10-20 2017-10-20
US62/575,275 2017-10-20
US201762580303P 2017-11-01 2017-11-01
US62/580,303 2017-11-01
US201862623371P 2018-01-29 2018-01-29
US62/623,371 2018-01-29
PCT/US2018/056789 WO2019079772A1 (en) 2017-10-20 2018-10-19 SYSTEMS AND METHODS FOR GENETICALLY MODIFIED B-LYMPHOCYTES FOR EXPRESSING SELECTED ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023190846A Division JP7650336B2 (ja) 2017-10-20 2023-11-08 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法

Publications (3)

Publication Number Publication Date
JP2021500028A JP2021500028A (ja) 2021-01-07
JP2021500028A5 true JP2021500028A5 (cg-RX-API-DMAC7.html) 2021-11-25
JP7383607B2 JP7383607B2 (ja) 2023-11-20

Family

ID=66174267

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020522004A Active JP7383607B2 (ja) 2017-10-20 2018-10-19 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法
JP2023190846A Active JP7650336B2 (ja) 2017-10-20 2023-11-08 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法
JP2025038002A Pending JP2025090718A (ja) 2017-10-20 2025-03-11 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023190846A Active JP7650336B2 (ja) 2017-10-20 2023-11-08 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法
JP2025038002A Pending JP2025090718A (ja) 2017-10-20 2025-03-11 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法

Country Status (12)

Country Link
US (2) US11578118B2 (cg-RX-API-DMAC7.html)
EP (1) EP3697895A4 (cg-RX-API-DMAC7.html)
JP (3) JP7383607B2 (cg-RX-API-DMAC7.html)
KR (2) KR102723182B1 (cg-RX-API-DMAC7.html)
CN (2) CN119265240A (cg-RX-API-DMAC7.html)
AU (2) AU2018351072B9 (cg-RX-API-DMAC7.html)
BR (1) BR112020007823A2 (cg-RX-API-DMAC7.html)
CA (1) CA3079681A1 (cg-RX-API-DMAC7.html)
IL (1) IL274082B2 (cg-RX-API-DMAC7.html)
MX (1) MX428371B (cg-RX-API-DMAC7.html)
SG (1) SG11202003024WA (cg-RX-API-DMAC7.html)
WO (1) WO2019079772A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108486125B (zh) * 2018-03-27 2024-01-05 重庆金迈博生物科技有限公司 一种核酸分子及其在制备人源单域抗体中的应用
WO2020053865A1 (en) * 2018-09-13 2020-03-19 Ramot At Tel-Aviv University Ltd. Genetic engneering of b cell receptors and uses thereof in antigen-induced antibody secretion
CN111995674B (zh) * 2020-09-03 2022-02-11 中国人民解放军军事科学院军事医学研究院 抗COVID-19病毒中和抗体mhC3及其人源化抗体与应用
WO2023192936A2 (en) * 2022-03-30 2023-10-05 Fred Hutchinson Cancer Center Systems and methods to produce b cells that express selected antibodies and gene products
AU2023269134A1 (en) * 2022-05-09 2024-12-12 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2025096483A2 (en) * 2023-10-30 2025-05-08 Be Biopharma, Inc. Engineered cell preparations
CN121801968B (zh) * 2026-03-10 2026-07-03 南京拂晓生物科技有限公司 一种用于生物融合酶抗体制备的免疫动物模型构建方法及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102257A1 (en) * 1998-09-21 2002-08-01 Leslie Sid Johnson Human-murine chimeric antibodies against respiratory syncytial virus
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US20010034062A1 (en) * 2000-02-09 2001-10-25 Scott Koenig Antibody gene therapy with adeno-associated viral vectors
AU2001270252B2 (en) * 2000-07-03 2007-02-08 Catalent Pharma Solutions, Llc Expression vectors
AU7658101A (en) * 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
WO2006115800A2 (en) * 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
JP2009532027A (ja) * 2006-03-28 2009-09-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗igf−1r抗体およびその使用
AU2010232414A1 (en) * 2009-04-03 2011-10-13 Duke University Mouse models
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
JP2013508308A (ja) * 2009-10-23 2013-03-07 ガーバン インスティテュート オブ メディカル リサーチ 修飾可変ドメイン分子、ならびにその産生および使用方法
DK2521789T3 (en) * 2010-01-08 2017-03-27 Immusoft Corp VECTORS AND PROCEDURE FOR B-CELL TRANSDUCTION
EP2591000B1 (en) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
US8637035B2 (en) 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
CN103282385A (zh) 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
EP2663334A4 (en) 2011-01-10 2016-01-13 Univ Emory ANTIBODIES AGAINST INFLUENZA
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US20150056171A1 (en) * 2012-03-16 2015-02-26 University Of Rochester Methods of Predicting Clinical Outcome of Chronic Lymphocytic Leukemia
WO2013148256A2 (en) * 2012-03-27 2013-10-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the generation of immunoglobulin sequences
CN116622704A (zh) 2012-07-25 2023-08-22 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
MX380562B (es) 2012-12-12 2025-03-12 Broad Inst Inc Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
WO2014093709A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
US10993420B2 (en) * 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
WO2014204725A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
SG11201510327TA (en) 2013-06-17 2016-01-28 Broad Inst Inc Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
ES2777217T3 (es) 2013-06-17 2020-08-04 Broad Inst Inc Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias
JP6738728B2 (ja) 2013-06-17 2020-08-19 ザ・ブロード・インスティテュート・インコーポレイテッド 肝臓ターゲティングおよび治療のためのCRISPR−Cas系、ベクターおよび組成物の送達および使用
EP3011033B1 (en) 2013-06-17 2020-02-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
WO2014204723A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions
KR20250012194A (ko) 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
MX370565B (es) 2013-07-19 2019-12-17 Vib Vzw Miembros de la familia tnf modificados dirigidos.
WO2015065964A1 (en) 2013-10-28 2015-05-07 The Broad Institute Inc. Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
WO2015089419A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
KR20160097338A (ko) 2013-12-12 2016-08-17 더 브로드 인스티튜트, 인코퍼레이티드 뉴클레오티드 반복 장애에서의 crispr-cas 시스템의 조성물 및 방법 및 용도
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
CN105899658B (zh) * 2013-12-12 2020-02-18 布罗德研究所有限公司 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
CA2932439A1 (en) 2013-12-12 2015-06-18 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
WO2015089473A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
NZ722391A (en) 2014-02-04 2022-12-23 Biogen Ma Inc Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
ES2755957T3 (es) 2014-03-31 2020-04-24 Univ Texas Anticuerpos de tos ferina humanizados y usos de los mismos
US11897921B2 (en) 2014-12-09 2024-02-13 New York University Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
CA2981077A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2017106657A1 (en) 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
US20190264186A1 (en) 2016-01-22 2019-08-29 The Broad Institute Inc. Crystal structure of crispr cpf1

Similar Documents

Publication Publication Date Title
US20220363771A1 (en) Multispecific antibodies
JP2022164824A (ja) 発現強化座位の使用に基づく抗体を作製するための組成物および方法
JP7650336B2 (ja) 選択された抗体を発現するように遺伝子改変されたb細胞を産生するシステム及び方法
JP2024016201A5 (cg-RX-API-DMAC7.html)
CN106573986A (zh) 多特异性抗体
JP2025134707A5 (cg-RX-API-DMAC7.html)
TWI922434B (zh) 一種融合蛋白及其用途
JP2014515598A (ja) 二重特異性三鎖抗体様分子
CA3145385A1 (en) Antibody compositions for disrupting biofilms
CN113710688A (zh) 用于治疗血液癌症和实体瘤癌症的嵌合抗原受体修饰的t细胞(car-t)
WO2016145385A2 (en) Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails
JP2022185053A (ja) 腸内消化に対する改善された安定性を有する抗体
JP2024546759A5 (cg-RX-API-DMAC7.html)
WO2022060906A1 (en) Coronavirus antibodies and uses thereof
EP4628095A1 (en) Fusion protein and granulated antigen comprising same
CN109929033A (zh) 一种特异性结合四种血清型登革病毒的人源抗体
CN101831434B (zh) 抗人cd45ra鼠免疫球蛋白可变区基因及用途
JP2025500806A5 (cg-RX-API-DMAC7.html)
CN120399078B (zh) 靶向cd117的纳米抗体及其应用
JP2025500805A5 (cg-RX-API-DMAC7.html)
CN103087155A (zh) 一种狂犬病毒疫苗增效蛋白及编码该蛋白的基因和应用
WO2017156423A2 (en) Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
EP3525813B1 (en) Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
RU2815823C2 (ru) Выделенное биспецифическое антитело, которое специфически связывается с CD47 и PD-L1
CN100412193C (zh) 抗人cd19鼠免疫球蛋白可变区基因及用途